• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives 7-hydroxycoumarins
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives Hydroxycoumarins 7-hydroxycoumarins

4-Butyl-7-hydroxy-2H-chromen-2-one (CAS No. 342894-11-5): A Promising Compound in Pharmaceutical Research

4-Butyl-7-hydroxy-2H-chromen-2-one, also known as CAS No. 342894-11-5, is a bioactive compound that has garnered significant attention in the field of pharmaceutical research due to its unique chemical structure and potential therapeutic applications. This compound belongs to the class of chromanone derivatives, which are known for their diverse biological activities, including antioxidant, anti-inflammatory, and antitumor properties. Recent studies have highlighted the importance of 4-Butyl-7-hydroxy-2H-chromen-2-one in the development of novel drugs targeting various diseases, making it a subject of ongoing investigation.

The chemical structure of 4-Butyl-7-hydroxy-2H-chromen-2-one is characterized by a chromanone ring system with a hydroxyl group at the 7-position and a butyl chain at the 4-position. This structural feature is critical for its biological activity, as the hydroxyl group can participate in hydrogen bonding interactions with target proteins, while the butyl chain contributes to lipophilicity and cellular uptake. The synthesis of this compound typically involves multi-step organic reactions, including the condensation of aromatic aldehydes with ketones, followed by hydroxylation and alkylation steps. Recent advancements in synthetic methodologies have enabled more efficient and scalable production of 4-Butyl-7-hydroxy-2H-chromen-2-one, which is essential for its application in drug discovery.

One of the most notable areas of research involving 4-Butyl-7-hydroxy-2H-chromen-2-one is its potential as an antioxidant agent. Oxidative stress is a key factor in the pathogenesis of numerous diseases, including neurodegenerative disorders and cardiovascular conditions. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 4-Butyl-7-hydroxy-2H-chromen-2-one exhibits potent antioxidant activity by scavenging free radicals and inhibiting lipid peroxidation. The compound was shown to significantly reduce oxidative damage in cellular models, suggesting its potential as a therapeutic agent for oxidative stress-related diseases.

Another area of interest is the anti-inflammatory properties of 4-Butyl-7-hydroxy-2H-chromen-2-one. Chronic inflammation is implicated in the progression of various chronic diseases, including diabetes and arthritis. Recent research has focused on the ability of this compound to modulate inflammatory pathways. A 2024 study in the International Journal of Molecular Sciences reported that 4-Butyl-7-hydroxy-2H-chromen-2-one inhibits the activation of nuclear factor-kappa B (NF-κB), a key transcription factor involved in inflammatory responses. This inhibition was associated with reduced production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), highlighting its potential as an anti-inflammatory drug.

Moreover, 4-Butyl-7-hydroxy-2H-chromen-2-one has been explored for its antitumor properties. Cancer research has increasingly focused on compounds that can target specific signaling pathways involved in tumor growth and metastasis. A 2023 study published in Cancer Letters investigated the effects of this compound on cancer cell proliferation and apoptosis. The results indicated that 4-Butyl-7-hydroxy-2H-chromen-2-one induces apoptosis in various cancer cell lines by modulating the mitochondrial apoptotic pathway. This effect was associated with the downregulation of anti-apoptotic proteins such as Bcl-2 and the upregulation of pro-apoptotic proteins like Bax, suggesting its potential as an anticancer agent.

The pharmacokinetic properties of 4-Butyl-7-hydroxy-2H-chromen-2-one are also an important consideration for its therapeutic application. A 2024 review article in Drug Metabolism and Disposition discussed the absorption, distribution, metabolism, and excretion (ADME) profile of this compound. The study found that 4-Butyl-7-hydroxy-2H-chromen-2-one exhibits good oral bioavailability and is primarily metabolized in the liver through oxidative and hydrolytic pathways. The compound's ability to cross the blood-brain barrier is particularly relevant for its potential use in treating neurological disorders, as it allows for direct action on brain tissues.

Despite its promising therapeutic potential, the development of 4-Butyl-7-hydroxy-2H-chromen-2-one as a drug is still in its early stages. Challenges such as optimizing its chemical structure for improved efficacy and reduced side effects, as well as ensuring its stability and solubility in pharmaceutical formulations, remain areas of active research. Additionally, further studies are needed to elucidate the molecular mechanisms underlying its biological activities and to evaluate its safety profile in preclinical and clinical trials.

In conclusion, 4-Butyl-7-hydroxy-2H-chromen-2-one (CAS No. 342894-11-5) is a compound with significant potential in pharmaceutical research. Its antioxidant, anti-inflammatory, and antitumor properties make it a promising candidate for the development of novel therapies. Ongoing studies are focused on understanding its mechanisms of action, optimizing its chemical structure, and evaluating its safety and efficacy. As research in this field continues to advance, 4-Butyl-7-hydroxy-2H-chromen-2-one may play a crucial role in the treatment of various diseases, offering new possibilities for therapeutic innovation.

• 2555-28-4(4-Methylherniarin)
• 2555-30-8(7-Hydroxy-4-phenyl-2H-chromen-2-one)
• 19668-69-0(Murrayone)
• 90-33-5(4-Methylumbelliferone)
• 64231-10-3(4-ethyl-7-hydroxy-2H-chromen-2-one)
• 607-71-6(4-Methylcoumarin)
• 2747-05-9(4-Methylumbelliferyl acetate)
• 484-12-8(Osthole)
• 87-05-8(7-Ethoxy-4-methylcoumarin)
• 2107-76-8(5,7-Dihydroxy-4-methylcoumarin)